Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 2.27 | -0.73 | 1.22 |
| FCF Yield | 1.41% | -0.09% | 0.25% | 1.00% |
| EV / EBITDA | 46.46 | 129.20 | 141.09 | 139.51 |
| Quality | ||||
| ROIC | 7.94% | 3.17% | 2.56% | 3.42% |
| Gross Margin | 70.23% | 65.93% | 58.36% | 54.44% |
| Cash Conversion Ratio | 0.97 | 0.34 | 0.82 | 2.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.71% | -2.90% | -1.93% | -2.25% |
| Free Cash Flow Growth | 1,747.98% | -132.01% | -76.37% | 120.88% |
| Safety | ||||
| Net Debt / EBITDA | -0.59 | 2.68 | -0.97 | 2.67 |
| Interest Coverage | 100.81 | 39.95 | 36.60 | 18.51 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.17 | 0.20 | 0.27 |
| Cash Conversion Cycle | 387.14 | 511.93 | 386.51 | 306.29 |